Biogen Q3 2026 Results: Net Loss of $20.6M
Biogen Inc. filed its Q3 2026 10-Q reporting on the quarterly period ended September 30, 2026. The filing highlights the company's strategic focus on product launches like LEQEMBI and SKYCLARYS, as well as the integration of acquisitions such as Reata, HI-Bio, and Apellis.
- Key figure
- Net loss $20.6M